Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrocell Science (FCSC)

Fibrocell Science (FCSC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,982
  • Shares Outstanding, K 9,758
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,280 K
  • 60-Month Beta 1.66
  • Price/Sales 1.35
  • Price/Cash Flow N/A
  • Price/Book 1.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +62.30%
on 09/12/19
2.98 -0.34%
on 10/10/19
+1.09 (+57.98%)
since 09/11/19
3-Month
1.70 +74.71%
on 08/12/19
2.98 -0.34%
on 10/10/19
+1.13 (+61.41%)
since 07/11/19
52-Week
1.45 +104.83%
on 12/31/18
3.28 -9.45%
on 03/20/19
+1.07 (+56.32%)
since 10/11/18

Most Recent Stories

More News
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - UCFC, SEMG, ALDR, FCSC

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

UCFC : 10.51 (+0.48%)
SEMG : 15.96 (-0.19%)
ALDR : 18.87 (-0.05%)
FCSC : 2.97 (+0.34%)
Due to Rising Prevalence of Cancer in U.S., Cancer Therapy Market Showing Rapid Growth

The global cancer therapy market looks like it will continue trend to continue its growth, worldwide. Cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific...

MBRX : 1.01 (unch)
FCSC : 2.97 (+0.34%)
NTEC : 0.73 (+1.58%)
MNK : 2.30 (+1.32%)
IMMU : 14.17 (+1.29%)
Fibrocell Up on FDA Designation for Gene Therapy Candidate

Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

FCSC : 2.97 (+0.34%)
ANIK : 57.11 (+1.47%)
XON : 6.02 (+3.97%)
AXGT : 5.72 (-4.35%)
Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?

Is (FCSC) Outperforming Other Medical Stocks This Year?

FCSC : 2.97 (+0.34%)
The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business

The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business

FBIZ : 23.96 (+2.00%)
CAC : 42.44 (+0.07%)
HIIQ : 26.42 (+6.62%)
FCSC : 2.97 (+0.34%)
LMB : 4.91 (+4.91%)
Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1

Fibrocell (FCSC) misses estimates for earnings and sales in the first quarter of 2019.

FCSC : 2.97 (+0.34%)
Small Business Optimism Hits 4-Month High in April: 5 Picks

Small corporates create significant amount of jobs in the U.S. economy.

FBIZ : 23.96 (+2.00%)
CAC : 42.44 (+0.07%)
HIIQ : 26.42 (+6.62%)
FCSC : 2.97 (+0.34%)
LMB : 4.91 (+4.91%)
Is Fibrocell Science (FCSC) Outperforming Other Medical Stocks This Year?

Is (FCSC) Outperforming Other Medical Stocks This Year?

FCSC : 2.97 (+0.34%)
Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates

Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.

RHHBY : 36.1500 (+0.44%)
BPMC : 73.67 (+2.40%)
FCSC : 2.97 (+0.34%)
CLSN : 1.66 (+0.61%)
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

GNMSF : 196.0000 (+2.05%)
GBT : 46.53 (+1.22%)
GILD : 63.99 (+1.15%)
FCSC : 2.97 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade FCSC with:

Business Summary

Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous...

See More

Key Turning Points

2nd Resistance Point 2.98
1st Resistance Point 2.97
Last Price 2.97
1st Support Level 2.96
2nd Support Level 2.96

See More

52-Week High 3.28
Last Price 2.97
Fibonacci 61.8% 2.58
Fibonacci 50% 2.37
Fibonacci 38.2% 2.15
52-Week Low 1.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar